Fenster schließen  |  Fenster drucken

Hier der Originalwortlaut und die richte Seite:
www.stockhouse.co.uk (natürlich nicht gbr, so ein quatsch)



PPL hopes its piglets will help to prevent organ rejection


THURSDAY APRIL 12 2001

PPL unveils modified piglets

BY MARK COURT, HEALTH INDUSTRIES CORRESPONDENT

PPL THERAPEUTICS, the biotechnology company that was forced to abandon a £45 million fundraising this week, yesterday bounced back when it became the world’s first company to produce genetically modified piglets as part of its attempt to transplant pig organs into people.

The five piglets are both transgenic, in that they have had a non-pig gene inserted into their chromosomes, and cloned, so their genetic make-up is identical.

Alan Colman, PPL research director, said: “This exciting world first again demonstrates PPL’s ability to apply its technical expertise to unmet medical needs such as the worldwide organ shortage.’’

PPL now intends to produce a transgenic piglet with a genetic modification in an attempt to prevent the rejection of pig organs if they were to be transplanted into people.

Clinical trials might begin in four to five years’ time and the market for organs such as lungs is estimated to be worth $5 billion.

Ron James, managing director of PPL, the company which created Dolly the sheep, yesterday bought 10,000 shares to underline his confidence in the company, which is being forced to explore funding alternatives after the failure of its £45 million cash call on Tuesday.

PPL is thought to be considering a smaller cash call of up to £25 million, which could probably be raised from existing shareholders. The company, whose shares closed down 2p yesterday at 111p, has enough cash for one year but needs longer-term funding in the next few months.



Copyright 2001 Times Newspapers Ltd. This service is provided on Times Newspapers` standard terms and conditions. To inquire about a licence to reproduce material from The Times, visit the Syndication website.





Breaking
Business News
from PA

April 12, 2001 09:24
 
aus der Diskussion: PPL-Therapeutics
Autor (Datum des Eintrages): schnirchel  (12.04.01 10:55:16)
Beitrag: 3 von 9 (ID:3293748)
Alle Angaben ohne Gewähr © wallstreetONLINE